Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission

By I. Katona, E. Rancz, L. Acsády, C. Ledent, K. Mackie, N. Hájos, Tamás F. Freund. Journal of Neuroscience, 2001

660 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/7984c29ac78a0eeea4e2ffea3f63a88664c2d9d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. K. Mackie
2. Denis Paré
3. Tamás F. Freund
4. I. Katona
5. P. Pacher
6. S. Batkai
7. Cyril Herry
8. Andreas Lüthi

In Pharmacology

1. K. Mackie
2. Tamás F. Freund
3. I. Katona
4. P. Pacher
5. S. Batkai
6. George Kunos
7. L. Iversen
8. Allyn C. Howlett

Citations in the corpus

• Dendritic excitability and synaptic plasticity. (2008, neutral): “some amygdala nuclei (356), and in hippocampus (13,”
• Cannabinoid physiology and pharmacology: 30 years of progress. (2004, background): “Combined with electron microscopy and electrophysiology studies, CB 1 receptors have been shown to be localized presynaptically on GABAergic interneurons (Katona et al., 1999, 2001).”
• Amygdala inhibitory circuits and the control of fear memory. (2009, background): “Although previous research has mostly focused on the role of glutamatergic transmission and plasticity, there is accumulating evidence indicating that local inhibitory circuits in the amygdala contribute to, or even mediate, important aspects of fear conditioning and extinction.”
• AMYGDALA MICROCIRCUITS CONTROLLING LEARNED FEAR (2014, background): “Indeed, CB1 receptors are only found on the axon terminals of a specific subpopulation of BLA interneurons, which express the peptide cholecystokinin (CCK) (Katona et al., 2001).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…and anterior cingular cortex, key regions in the regulation of anxiety, may suggest that the endocannabinoid system plays a role in the control of anxiety (Herkenham et al., 1990, 1991a,b; Glass et al., 1997b; Katona et al., 2001; Hájos and Freund, 2002; Tzavara et al., 2003; Pistis et al., 2004).”
• Involvement of the endocannabinoid system in drug addiction. (2006, background): “The presence of CB1 receptors in other structures related to motivation and reward, such as the basolateral amygdala and the hippocampus, also contributes to this function of the endocannabinoid system [ 16 ].”
• Cannabis and the brain. (2003, background): “For example, Katona et al. (2001) reported that CB1 receptors were expressed in high densities in lateral and basal nuclei in the rat amygdala.”
• Distribution of cannabinoid receptors in the central and peripheral nervous system. (2005, background): “The second is that double label immunostaining experiments demonstrated that in forebrain there is a striking correlation between CCK and CB1 receptor expression (Katona et al. 1999; Tsou et al. 1999; Katona et al. 2001).”
• Role of endogenous cannabinoids in synaptic signaling. (2003, background): “In support of this idea, correlated light and electron microscopy using high-resolution immunogold technique provide clear-cut evidence that the CB1 immunostaining visualizing cell bodies and proximal dendrites of interneurons at the light microscopical level is always associated with intracellular ”